The Effect Of Aspirin On Survival in in Patients Undergoing Chronic Hemodialysis

Hemodialysis Clinical Trial

Official title:

The Effect Of Aspirin On Survival in in Patients Undergoing Chronic Hemodialysis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02261025
• Other study ID #: 20120308
• Status: Completed
• Phase: N/A
• First received: October 6, 2014
• Last updated: October 22, 2014
• Start date: January 2008
• Est. completion date: September 2014

Study information

• Verified date: October 2014
• Source: Shanghai Jiao Tong University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The aim of present study is to examine the effect of low-dose aspirin on the incidence of cardiovascular events and mortality in patients undergoing chronic hemodialysis.

Description:

This study prospectively evaluate the impacts of low dose aspirin on survival and cardio-cerebral vascular events in a large cohort of Chinese patients undergoing chronic hemodialysis. Between January 2008, consecutive patients with hemodialysis with aspirin were enrolled.We examine the association of aspirin with all-cause mortality in patients matched by propensity scores using the Kaplan-Meier method and Cox models in "intention-to-treat" analyses.The secondary endpoint was rate of cardio-cerebral events.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 410
• Est. completion date: September 2014
• Est. primary completion date: September 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

All patients aged 18 to 85, undergoing chronic hemodialysis, who have none of the following exclusion criteria.

Exclusion Criteria:

History of gastric or duodenal ulcers Known allergy to aspirin or other NSAIDs

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Hemodialysis

Intervention

Drug:
• acetylsalicylic acid
75-100mg,per day

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Jiao Tong University School of Medicine

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	survival rate		5 years	Yes
Secondary	cardio-cerebral event		5 years	Yes